Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

18 Nov 2021

Abstract excerpt

. CV2CoV is a second-generation mRNA vaccine containing non-modified nucleosides but with optimized non-coding regions and enhanced antigen expression. Here we report the results of a head-to-head comparison of the immunogenicity and protective efficacy of CVnCoV and CV2CoV in non-human primates. We immunized 18 cynomolgus macaques with two doses of 12 μg lipid nanoparticle-formulated CVnCoV or CV2CoV or with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to Immunotherapy and Immune Responses
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34794169
DOI: 10.1038/s41586-021-04231-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccinePMID 34794169Read ↗

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman PrimatesSemantic proximity Read ↗

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read ↗

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodentsSemantic proximity Read ↗

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studiesSemantic proximity Read ↗

An Update on mRNA-Based Viral VaccinesSemantic proximity Read ↗

Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variantsSemantic proximity Read ↗

Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2Semantic proximity Read ↗

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosineSemantic proximity Read ↗

Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variantsSemantic proximity Read ↗

Combinatorial mRNA vaccination enhances protection against SARS-CoV-2 delta variantSemantic proximity Read ↗

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody ResponsesSemantic proximity Read ↗

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.